

**Submission
No 38**

INQUIRY INTO DRUG AND ALCOHOL TREATMENT

Organisation: Christian Democratic Party
Name: The Rev The Hon Fred Nile MLC
Date received: 1/03/2013



The Rev. The Hon. Fred Nile MLC ED., L.Th.,

Member of the Legislative Council
Assistant President of The Legislative Council
Parliamentary Leader, Christian Democratic Party
Parliament House, Macquarie Street, SYDNEY NSW 2000
Telephone: (02) 9230 2478 Facsimile: (02) 9230 2098
Email: f.nile@parliament.nsw.gov.au



Friday, 1st March 2013

The Hon Marie Ficarra MLC

Chairman
General Purpose Standing Committee No. 2
Parliament House
Macquarie St
Sydney NSW 2000

Dear Hon Marie Ficarra,

Please find herewith our Submission to the Drug and Alcohol treatment to assist your Inquiry.

We strongly support a Naltrexone Impact Trail facility in New South Wales, following the Dr George O'Neil - Fresh Start Clinic in Perth, Western Australia model (refer attached background material on the Fresh Start Clinic, WA.)

Submission includes:

Second Reading Speech – by Rev Hon Fred Nile - 25 October 2012

- Second Reading - Drug and Alcohol Treatment Amendment (Rehabilitation of Persons with Severe Substance Dependence) Bill 2012 – 25 October 2012 – Legislative Council

Papers: - These papers demonstrate the widespread academic support for the Naltrexone especially the implant method)

- *Vascular Ageing in Opioid Pharmacotherapy* – by Dr Albert Stuart Reece & Dr Gary Kenneth Hulse
- *Vascular Age Reduction following Opiate Abstinence* by Dr Albert Stuart Reece

Supporting Journal/Articles

- Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. *Arch Gen Psychiatry* 2009;66(10):1108-15.
- Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. *Current psychiatry reports* 2010;12(5):448-53.
- Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. *Lancet* 2011;377(9776):1506-13.

- Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy Podosenin M, et al. Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence. *Archives of general psychiatry* 2012;69(9):973-81.
- Kunøe N, Lobmaier P, Ngo H, Hulse GK. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. *British Journal of Clinical Pharmacology* 2012:n/a-n/a.
- Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users. *Addict Biol* 2003;8(3):337-42.
- Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. *J Subst Abuse Treat* 2008;35(2):116-24.
- Bart G. Promise of extended-release naltrexone is a red herring. *Lancet* 2011;378(9792):663; author reply 63-4.
- Improving Clinical Outcomes for Naltrexone as a Management of Problem Alcohol Use By Dr Gary Hulse – Porfessor of Addition Medicine.
- CV's of Dr A S Reece, Dr G K Hulse and Dr George O'Neil

We also attach volumes 1 & 2 "Naltrexone – Highway to Freedom" a policy source document as presented by Dr A S Reece – (refer attached CV).

Thank you for the opportunity to make a submission on this most important social issue.

Yours sincerely

Rev Hon Fred Nile MLC
Christian Democratic Party